Guijarro, Luis GCano-Martínez, DavidToledo-Lobo, M ValRuiz-Llorente, LidiaChaparro, MaríaGuerra, IvánIborra, MarisaCabriada, José LuisBujanda, LuisTaxonera, CarlosGarcía-Sánchez, ValleMarín-Jiménez, IgnacioBarreiro-de Acosta, ManuelVera, IsabelMartín-Arranz, María DoloresMesonero, FranciscoSempere, LauraGomollón, FernandoHinojosa, JoaquínZoullas, SofíaMonserrat, JorgeMenor-Salvan, CesarAlvarez-Mon, MelchorGisbert, Javier POrtega, Miguel AHernández-Breijo, Borja2023-05-032023-05-032022-03-212227-9059http://hdl.handle.net/10668/20825Background: Recently, increased tissue levels of AIF-1 have been shown in experimental colitis, supporting its role in intestinal inflammation. Therefore, we studied the levels of AIF-1 in Crohn’s disease (CD). Methods: This study included 33 patients with CD (14 men and 19 women) who participated in the PREDICROHN project, a prospective multicenter study of the Spanish Group of Inflammatory bowel disease (GETECCU). Results: This article demonstrates declines with respect to baseline levels of serum AIF-1 in Crohn’s disease (CD) patients after 14 weeks of treatment with anti-TNFs. Furthermore, in patients with active CD (HB ≥ 5), serum AIF-1 levels were significantly higher than those in patients without activity (HB ≤ 4). The study of serum AIF-1 in the same cohort, revealed an area under the ROC curve (AUC) value of AUC = 0.66 (p = 0.014), while for the CRP (C-reactive protein), (AUC) value of 0.69 (p = 0.0066), indicating a similar ability to classify CD patients by their severity. However, the combination of data on serum levels of AIF-1 and CRP improves the predictive ability of these analyses for classifying CD patients as active (HB ≥ 5) or inactive (HB ≤ 4). When we used the odds ratio (OR) formula, we observed that patients with CRP > 5 mg/L or AIF-1 > 200 pg/mL or both conditions were 13 times more likely to show HB ≥ 5 (active CD) than were those with both markers below these thresholds. Conclusion: The development of an algorithm that includes serum levels of AIF-1 and CRP could be useful for assessing Crohn’s disease severity.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/AIF-1CRPCrohn’s diseaseanti-TNFsresearch article35327530open access10.3390/biomedicines10030727PMC8945466https://www.mdpi.com/2227-9059/10/3/727/pdf?version=1648022117https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945466/pdf